Anticoagulants for acute respiratory distress syndrome: can they work?
about
Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysisSurfactant therapy for acute lung injury and acute respiratory distress syndrome.Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits.Critical care medicine in AJRCCM 2001.Plasminogen activators in inflammation and sepsis.Building a better heparin.Adult respiratory distress syndrome: do selective anticoagulants help?Mechanisms of alveolar protein clearance in the intact lung.Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.Regulation of ENaC-mediated alveolar fluid clearance by insulin via PI3K/Akt pathway in LPS-induced acute lung injuryFeasibility of tissue plasminogen activator formulated for pulmonary delivery.Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management.Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats.Pharmacotherapy of acute lung injury and acute respiratory distress syndromeIntra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity.Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigationsNatural and synthetic products used for the treatment of smoke inhalation: a patent review.Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier.Antihistone Properties of C1 Esterase Inhibitor Protect against Lung Injury.Protein C and thrombomodulin in human acute lung injury.Naringenin ameliorates LPS-induced acute lung injury through its anti-oxidative and anti-inflammatory activity and by inhibition of the PI3K/AKT pathway.Role of heparin in pulmonary cell populations in an in-vitro model of acute lung injury.Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide.Pulmonary net release of tissue-type plasminogen activator during porcine primary and secondary acute lung injury.Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury.Anticoagulant therapy in acute respiratory distress syndrome.Blockade of tissue factor: treatment for organ injury in established sepsis.Effect of covalent serpin-heparinoid complexes on plasma thrombin generation on fetal distal lung epithelium.Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.Writing a Review Article forAJRCCM
P2860
Q26753103-22172A87-110C-4E6B-B7A1-60136958992EQ30426177-548F6C4F-2148-4121-B475-13A0C6ED0C4BQ30532487-5C5615C2-8E9E-47F0-9E92-47CC0D170DABQ34550121-2EF24B4F-1C43-45E3-BB84-1DD365AD9B52Q34777701-B8197912-10D5-436B-BF48-9921E98338BDQ35050511-C6EC5E17-084C-49D5-AC2F-1B33829A77A8Q35627757-DF27635E-2120-4BB4-8045-A452CAAB110BQ35683691-49224D49-7794-4135-95F8-41A2EA27C392Q35855114-41656D8A-90D2-459A-A380-3D3DE5B76C3BQ35996407-1A18DC7A-3413-4BDE-BF22-DCC02FE9EB6EQ36088869-8C680F97-444E-488C-9A53-17BA515A8E07Q36261456-E7572168-C7E5-459E-82B2-F000807C1470Q36507496-F2660380-A02F-4995-B654-3087CD801EC5Q37085611-792F2711-1E61-4F5A-AD47-B7F3FFF567EAQ37393718-EDD7A4E7-11EA-4810-92E2-903AE90995ABQ38006576-6E490D24-00AC-4FEB-BCEA-81B360505AFCQ38737817-852D570A-504F-4845-A58E-0B891DBDFB54Q40287076-9B3D319D-96A5-428B-83E0-6D599C465357Q40398984-8905ACF7-7BD5-4EB0-B6AF-DBE9635BFC11Q40646976-C67D17D3-942E-4C7B-A622-466AD6881395Q41672383-26EF22EB-ED10-4097-9367-F44F389C6A6DQ41833312-2F3E46B4-82F0-4BE6-8033-3D58FC2F8A2CQ42074872-B22F5F2F-13E3-4C89-9331-CB1851EEAC02Q46406279-5D4A1D80-7FF1-4E17-9AA6-FF9A8F504360Q47227592-802DCDC5-CF12-4BC3-8480-CB0DCCF4B703Q47934955-44F8AE68-F9EB-406B-BB67-443A0710ACEAQ50072766-BD3C6FE5-A964-4F3A-8AAF-46C2ED7B2A57Q51676119-763B845C-AB28-4436-8601-5AC68A8BC3DDQ51689662-B3018399-3852-40E2-93D4-198E0BA0C243Q53470284-506B6F8A-B301-4ABC-9BFE-3E93C6CBBE0CQ56457060-E2BAA79A-D614-4739-9FCD-C142EA052BC7
P2860
Anticoagulants for acute respiratory distress syndrome: can they work?
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Anticoagulants for acute respiratory distress syndrome: can they work?
@ast
Anticoagulants for acute respiratory distress syndrome: can they work?
@en
Anticoagulants for acute respiratory distress syndrome: can they work?
@nl
type
label
Anticoagulants for acute respiratory distress syndrome: can they work?
@ast
Anticoagulants for acute respiratory distress syndrome: can they work?
@en
Anticoagulants for acute respiratory distress syndrome: can they work?
@nl
prefLabel
Anticoagulants for acute respiratory distress syndrome: can they work?
@ast
Anticoagulants for acute respiratory distress syndrome: can they work?
@en
Anticoagulants for acute respiratory distress syndrome: can they work?
@nl
P2860
P1476
Anticoagulants for acute respiratory distress syndrome: can they work?
@en
P2093
P2860
P304
P356
10.1164/AJRCCM.164.4.2102095
P407
P577
2001-08-01T00:00:00Z